• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Nordics

VC-backed Ascendis raises $108m in IPO

  • Ellie Pullen
  • 29 January 2015
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Ascendis Pharma, a Danish biotech backed by a consortium of VCs including Sofinnova Partners and Gilde Healthcare Partners, has listed on the Nasdaq.

The company sold 6 million shares, meaning it has raised $108m in total from the listing.

The business listed on the Nasdaq on 28 January, with a market cap of $394.8m, under the ticker "ASND".

Bank of America Merrill Lynch and Leerink Partners were appointed as joint bookrunning managers for the flotation. Wells Fargo Securities acted as co-manager.

Ascendis has received funding in the past from France-based Sofinnova Partners, US-based Sofinnova Ventures, Gilde Healthcare Partners, OrbiMed, Vivo Capital and German venture capital firm Technostart.

According to the company's F-1 filing with the US Securities and Exchange Commission, Sofinnova Partners – via its Sofinnova Capital V fund – is one of the company's largest shareholders with a 25.9% stake following the offering.

Gilde Healthcare now holds a 13% shareholding, while Technostart owns 8%, Sofinnova Ventures and OrbiMed each own 7.2% and Vivo holds 6%.

Previous funding
In December 2007, Ascendis raised €17.5m its series-A round from Gilde Healthcare, Sofinnova Partners and Technostart. Gilde invested via its €150m Gilde Healthcare II fund. Sofinnova led the round.

In December last year, the company secured a further $60m from OrbiMed, Sofinnova Ventures, Venrock Ventures, RA Capital, Vivo and Epidarex Capital (formerly Rock Spring Ventures).

Company
Founded in 2007, Ascendis is headquartered in Copenhagen with an additional office in Palo Alto and research and development sites in Heidelberg in Germany and Copenhagen.

The company has developed its TransCon technology, which is designed to create product candidates that are improved versions of existing drugs.

Ascendis generated €20.4m in revenues in 2013. It employs 55 staff.

People
Jan Møller Mikkelsen is the CEO of Ascendis. The company's board of directors includes Sofinnova Partners managing partner Rafaèle Tordjman, OrbiMed partner Jonathan Silverstein, Technostart founder Michael Mayer, Sofinnova Ventures partner James Healy, Gilde Healthcare managing partner Edwin de Graaf and Vivo managing partner Albert Cha.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Nordics
  • Healthcare
  • Exits
  • IPO
  • NASDAQ
  • Denmark
  • Sofinnova
  • Sofinnova Partners
  • Gilde Investment Management

More on Nordics

VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept
VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept

The GP expects to launch its second fund in 2025 with a target size of EUR 100m-EUR 125m

  • Nordics
  • 16 August 2023
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs

Stockholm-based investor is considering divestments, although challenging market remains a barrier

  • Nordics
  • 26 May 2023
3i to invest in Danish children's brand Konges Sløjd
3i to invest in Danish children's brand Konges Sløjd

Deal aims to support the baby and children apparel group expand in Asia and the US

  • Nordics
  • 21 June 2022
HG-backed Visma to divest IT consulting unit to CVC
HG-backed Visma to divest IT consulting unit to CVC

Sponsor will invest in the carve-out from the Norwegian business software and IT provider via Fund VIII

  • Nordics
  • 16 June 2022

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013